| Company Name |
Medifron, Inc |
| Country |
Korea
|
| Web Address |
www.medifron.com
|
| Representative |
Hyun S. Muk
|
| Address |
240-21 Yeomchang-dong, Woolim Blue9, A1401, Gangseo-gu, Seoul, 157-861, KOrea
|
| Established |
1999 |
| Number of Employees |
37
|
| Industry by Sector |
Pharmaceutical /
Biotech /
|
| Products/Services |
Novel drug research & development
|
Capital
(Thousand US$) |
8000 (Thousand US$) |
Sales Revenue
(Thousand US$) |
7500 (Thousand US$) |
| Branches |
|
| « Company Overview |
Medifron, inc. is a public biopharmaceutical company listed in KOSDAQ with product candidates in drug development for unmet medical needs in the fields of neurology. Main targets of the company are Alzheimer’s disease and Neuropathic pain with strong and maturing pipeline of products.
|
| « Executive Summary |
We are seeking partner for global scale development as below:
1. Alzheimer's disease treatment whose MOA is "A-beta peptide aggregation inhibitor" and efficacy is proved at Transgenic Mice Model.
Stage at development: preparing for IND filing
2. Alzheimer's disease treatment - RAGE antagonist
RAGE is known as an active transporter of A-beta peptide from plasma to the brain
Efficacy: proved at Transgenic Mice model
Stage at development: lead optimization
We are seeking a partner for research collaboration and commercialisation
3. Neuropathic pain treatment of TRPV1 agonist for transdermal administration such as patch and/or cream stage at development: preclinical studies
|
|
Company Profile
